GO41767
10 Dec 2020
Trial Summary
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of Atezolizumab Plus Carboplatin And Etoposide With Or Without Tiragolumab (Anti-Tigit Antibody) In Patients With Untreated Extensive-Stage Small Cell Lung Cancer
Acronym:
SKYSCRAPER-02
ACTRN/NCT /ethics:
NCT04256421
Scientific title:
This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC).
Sponsor / Cooperative group:
Hoffmann-La Roche
Trial & Patient Characteristics
| Cancer Type | Lung & mesothelioma |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | ES-SCLC |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2020-02-04 |
| Anticipated End Date | 2023-09-29 |
Participating Hospitals
| Hospital | Lyell McEwin Hospital |
|---|---|
| Clinical Trial Coordinator | Andy Phay |
| andy.phay@sa.gov.au | |
| Phone | 08 8282 0833 |
| Principal Investigator | Dr Dainik Patel |
| Recruitment Status | Recruiting |